Table 5.
Main characteristics of the studies included. Patients treated with EUS-guided EA technique. NA: not applicable.
| Study population | Country | No. of patients with insulinoma | Gender (M\F) | Age (y) | Indication for EUS-EA | No of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| before EA | after EA | before EA | after EA | before EA | after EA | ||||||||||||
| Schnack et al. 45 | Denmark | 1 | M | 89 | comorbidity | 1 | NA | NA | 98 | 3.5 | NA | NA | NA | NA | NA | NA | mild AP |
| Silva et al. 46 | Brazil | 1 | F | 21 | comorbidity | 1 | NA | NA | 99 | 1.5 | NA | NA | NA | NA | NA | NA | no |
| Trevino et al. 47 | USA | 1 | F | 79 | tumour location (multiple ins.) | 2 | 1 | 2 | 98 | 12 | NA | NA | NA | NA | NA | NA | no |
| Trikudantha et al. 48 | USA | 1 | F | 66 | comorbidity | 1 | 1 | 4 | NA | 1 | 2.5 | NA | 228 | NA | 2473 | NA | no |
| Vleggaar et al. 49 | The Netherlands | 1 | F | 82 | comorbidity | 1 | NA | NA | 96 | 0.3 | 2.2 | 6.4 | 97.2 | 41.7 | 1820 | 910 | no |
| Zalewska et al. 51 | Poland | 1 | F | 72 | comorbidity | 1 | 2 | NA | 96 | 2 | 1.8 | NA | NA | NA | NA | NA | abd.pain |
| Zarug et al. 52 | USA | 1 | M | 56 | comorbidity | 1 | NA | NA | NA | 1.5 | 2.05 | NA | 252 | NA | NA | NA | no |